Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Jin Won | - |
dc.contributor.author | Lee, Jae Seung | - |
dc.contributor.author | Lee, Hye Won | - |
dc.contributor.author | Kim, Beom Kyung | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Lee, Han Ah | - |
dc.contributor.author | Kim, Mi Na | - |
dc.contributor.author | Lee, Yu Rim | - |
dc.contributor.author | Hwang, Seong Gyu | - |
dc.contributor.author | Rim, Kyu Sung | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Kweon, Young Oh | - |
dc.contributor.author | Park, Soo Young | - |
dc.contributor.author | Kim, Seung Up | - |
dc.date.accessioned | 2021-12-04T22:59:39Z | - |
dc.date.available | 2021-12-04T22:59:39Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/129466 | - |
dc.description.abstract | Several prediction scores for the early detection of hepatocellular carcinoma (HCC) are available. We validated the predictive accuracy of age, albumin, sex, liver cirrhosis (AASL), RESCUE-B, PAGE-B and modified PAGE-B (mPAGE-B) scores in chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir disoproxil fumarate (TDF). Between 2007 and 2014, 3171 patients were recruited (1645, ETV; 1517, TDF). The predictive accuracy of each prediction score was assessed. The mean age of the study population (1977 men; 1194 women) was 48.8 years. Liver cirrhosis was present in 1040 (32.8%) patients. During follow-up (median, 58.2 months), 280 (8.8%) patients developed HCC; these patients were significantly older; more likely to be male; had significantly higher proportions of liver cirrhosis, hypertension and diabetes; and had significantly higher values for the four risk scores than those who did not develop HCC (allP < .05). Older age (hazard ratio [HR] = 1.048), male sex (HR = 2.142), liver cirrhosis (HR = 3.144) and prolonged prothrombin time (HR = 2.589) were independently associated with an increased risk of HCC (allP < .05), whereas a higher platelet count (HR = 0.996) was independently associated with a decreased risk of HCC (P < .05). The predictive accuracy of AASL score was the highest for 3- and 5-year HCC predictions (areas under the curve [AUCs] = 0.818 and 0.816, respectively), followed by RESCUE-B, PAGE-B and mPAGE-B scores (AUC = 0.780-0.815 and 0.769-0.814, respectively). In conclusion, four HCC prediction scores were assessed in Korean CHB patients treated with ETV or TDF. The AASL score showed the highest predictive accuracy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | CLINICAL-PRACTICE GUIDELINES | - |
dc.subject | NATURAL-HISTORY | - |
dc.subject | SCORING SYSTEM | - |
dc.subject | MANAGEMENT | - |
dc.subject | CIRRHOSIS | - |
dc.subject | GENOTYPES | - |
dc.subject | THERAPY | - |
dc.title | Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.identifier.doi | 10.1111/jvh.13411 | - |
dc.identifier.scopusid | 2-s2.0-85092180683 | - |
dc.identifier.wosid | 000575785900001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VIRAL HEPATITIS, v.28, no.1, pp.95 - 104 | - |
dc.relation.isPartOf | JOURNAL OF VIRAL HEPATITIS | - |
dc.citation.title | JOURNAL OF VIRAL HEPATITIS | - |
dc.citation.volume | 28 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 95 | - |
dc.citation.endPage | 104 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | CLINICAL-PRACTICE GUIDELINES | - |
dc.subject.keywordPlus | NATURAL-HISTORY | - |
dc.subject.keywordPlus | SCORING SYSTEM | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordPlus | GENOTYPES | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | antiviral therapy | - |
dc.subject.keywordAuthor | chronic hepatitis B | - |
dc.subject.keywordAuthor | entecavir | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | risk prediction score | - |
dc.subject.keywordAuthor | tenofovir disoproxil fumarate | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.